127 replies
Vesugen
Also known as: Lys-Glu-Asp
Limited evidence
ClassShort peptide bioregulator
Research statusPreclinical / Russian clinical use
Independent tests1
Studies indexed1
Companies tested 1
Overview
A tripeptide bioregulator associated with vascular endothelium in the Khavinson framework.
Vesugen is classified as a short peptide bioregulator. Its current development status is: preclinical / russian clinical use. The published evidence is thin, largely non-independent, or does not address the uses this compound is marketed for.
The Peptide Institute tracks Vesugen because it is actively sold through research-compound and telehealth channels. Our interest is narrow and specific: what is actually in the vial, whether the label is accurate, and whether the sellers of it can document what they claim. We take no position on whether anyone should use it.
Independent Testing
Independently tested companies that sell Vesugen
Every company below was evaluated with product the Institute purchased anonymously and sent for third-party laboratory analysis. Ranked by Index Score™.
- Companies
- 1
- Samples
- 1
- Updated
- Sep 7, 2025
- 1 Vector Peptide Supply Good Institute
Top Rated Vesugen94.7% average purity across 1 sample
Purity & Testing 89 Transparency 52 Samples 1 70 View company
Research & Studies
Studies library-
Immunogenicity and stability profile of Vesugen
Characterises Vesugen activity in a controlled setting. Endpoints are surrogate measures rather than clinical outcomes.
Independent Testing
Testing databaseLaboratory verification of Vesugen products across the companies we index.
Vesugen Vector Peptide Supply
Purity 94.7% Verified
Community Discussions
Forum 8 replies
176 replies
The Peptide Institute Weekly
Research. Testing. Regulation. No hype.
One email a week: new study summaries, the latest independent lab results, ranking movements, and regulatory developments that matter.
- New research, summarized in plain English
- Independent lab results as they publish
- Score and ranking movements